GlassScriptPhysician profile
Amber Allison Choate
NPI 1134572357
$2,192.47
in general payments reported to CMS, 2019-2025
22 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $658 · 2022: $846 · 2023: $341 · 2024: $154 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $320.63 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $276.85 | 2022-2024 | |
| Glaxosmithkline, LLC. | $250.15 | 2021-2025 | Trelegy Ellipta |
| Amgen INC. | $205.00 | 2021-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $172.45 | 2021-2023 | |
| Daiichi Sankyo INC. | $155.09 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $149.41 | 2022 | |
| Abbott Laboratories | $138.68 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $125.99 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $69.18 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $57.42 | 2021 | |
| Radius Health, INC. | $47.08 | 2024-2025 | Tymlos |
| Amarin Pharma, INC. | $41.58 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $29.01 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.73 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $27.88 | 2021 | |
| Mylan Specialty L.P. | $20.73 | 2022 | |
| Pharmacosmos Therapeutics INC. | $16.30 | 2022 | |
| Biogen, INC. | $15.90 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.57 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $15.50 | 2021 | |
| Sumitomo Pharma America, INC. | $13.34 | 2024 | Myfembree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Choate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.